Nirav Ratia
YOU?
Author Swipe
View article: P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS
P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Multiple myeloma (MM) is an incurable malignant clonal plasma cell disorder and accounts for 1% of all cancers and 10% of all hematologic malignancies globally. Tr…
View article: Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐blind placebo‐controlled study
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐blind placebo‐controlled study Open
Aims To explore the safety, tolerability, pharmacokinetics and pharmacodynamics (PD) of GSK2646264 using skin challenge models. Methods Healthy volunteers (HV) with a positive allergen skin prick test received GSK2646264 (0.5% or 1% ww) an…
View article: Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double‐blind Phase Ib study
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double‐blind Phase Ib study Open
The immunoregulator spleen tyrosine kinase (SYK) is upregulated in cutaneous lupus erythematosus (CLE). This double‐blind, multicentre, Phase Ib study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effi…
View article: Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren’s syndrome
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren’s syndrome Open
Objectives To assess non-invasive imaging for detection and quantification of gland structure, inflammation and function in patients with primary Sjogren's syndrome (pSS) using PET-CT with 11C-Methionine (11C-MET; radiolabelled amino acid)…